News from can-fite biopharma A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 27, 2015, 07:00 ET

Can-Fite Reports Positive Results from Further Analysis of Phase II/III Psoriasis Trial

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that...

Apr 20, 2015, 07:00 ET

Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are...

Mar 30, 2015, 09:11 ET

Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Mar 27, 2015, 16:29 ET

Can-Fite Files 2014 Annual Report on Form 20-F

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are...

Mar 23, 2015, 07:00 ET

Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are...

Mar 18, 2015, 07:00 ET

Can-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being...

Feb 17, 2015, 07:00 ET

Can-Fite Receives Notice of Allowance in U.S. for Psoriasis Patent

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that are being...

Feb 04, 2015, 07:00 ET

Can-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Jan 27, 2015, 07:00 ET

Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Jan 06, 2015, 07:15 ET

Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

Dec 30, 2014, 07:00 ET

Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101

 Can-Fite BioPharma Ltd. (NYSE MKT:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Dec 22, 2014, 07:00 ET

Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

Dec 15, 2014, 07:02 ET

Second Part of the Glaucoma Phase II study has been Approved in a European Country

 Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company developing a pipeline of small...

Dec 09, 2014, 07:00 ET

Can-Fite to Initiate the Development Program of its Next Generation Drug CF602

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Dec 02, 2014, 17:49 ET

Can-Fite Announces $8 Million At-The-Market Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA),a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...

Dec 01, 2014, 07:00 ET

Can-Fite Reports Financial Results for Nine Months Ended September 30, 2014

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that...

Dec 01, 2014, 07:00 ET

US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...

Nov 18, 2014, 07:00 ET

Can-Fite Near-Term Milestones Timetable for 2014/2015

 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

Nov 17, 2014, 17:48 ET

Can-Fite Announces Special General Meeting of Shareholders to Elect External Director

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...

Nov 13, 2014, 07:00 ET

Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...